SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification
- Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events -